Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response

Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Tyvin A. Rich(The University of Texas MD Anderson Cancer Center), Christopher G. Willett, Gordon Okawara(The University of Texas MD Anderson Cancer Center), J.F. Greskovich(The University of Texas MD Anderson Cancer Center), Christopher H. Crane(Memorial Sloan Kettering Cancer Center), John H. Donohue(American Cancer Society), P.R. Anné(The University of Texas MD Anderson Cancer Center), Kathryn Winter(The University of Texas MD Anderson Cancer Center), Peter W. T. Pisters(The University of Texas MD Anderson Cancer Center), Jeffrey D. Bradley(Hospital of the University of Pennsylvania)
Journal of Clinical Oncology
August 18, 2006
10.1200/jco.2006.06.4840
Cited by 385

Related Papers

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.7k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.1k
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
Colon Cancer
|Journal of the National Comprehensive Cancer Network|2009|684